ArticleFrontiers in cellular and infection microbiology2025
Tryptophan metabolic reprogramming modulates cytokine networks in nucleos(t)ide analogue-treated chronic hepatitis B patients.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the gut: microbiota and derived metabolites' role in the rising tide of precocious puberty.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: Hepatitis B virus (HBV) infection remains a global health challenge. Tryptophan metabolism influences immune regulation, but its interplay with cytokines during antiviral therapy is unclear. We investigated associations between tryptophan pathways and cytokine profiles in the chronic hepatitis B (CHB) patients with varying treatment outcomes. Methods: This retrospective study included 106 CHB patients (including 29 functional cure cases) receiving nucleos(t)ide analogues (NAs) and 29 healthy controls. Plasma levels of 20 tryptophan metabolites (kynurenine, serotonin, and bacterial pathways) were quantified by HPLC-MS/MS, and 12 cytokines were measured via flow cytometry. Multivariate analyses were performed. Results: Functional cure patients showed unique metabolic patterns. Indole-3-carboxaldehyde (IAld) levels increased progressively from HBsAg positive groups (HBeAg-: 63.324 nmol/L; HBeAg+: 65.938 nmol/L) to functional cure (91.44 nmol/L) and healthy controls (130.634 nmol/L) ( Conclusions: The tryptophan metabolites (IAld, PA, 5-HT) were found to correlate with cytokine levels (IL-1β, IL-10), potentially implicating their involvement in immune regulation and antiviral responses. These observations delineate a metabolic-immune framework that may inform future therapeutic development for HBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.